164 related articles for article (PubMed ID: 24993455)
1. FDG PET/CT methodology for evaluation of treatment response in lymphoma: from "graded visual analysis" and "semiquantitative SUVmax" to global disease burden assessment.
Basu S; Zaidi H; Salavati A; Hess S; Carlsen PF; Alavi A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2158-60. PubMed ID: 24993455
[No Abstract] [Full Text] [Related]
2. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
3. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
4. Cervical lymph node hyperplasia on [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography scan after treatment of children and adolescents with malignant lymphoma.
Hu YY; Zhang X; Long W; Lin XP; Zhang YR; Li YH; Xiao ZZ; Zheng RL; Liang PY; Fan W
Eur J Radiol; 2015 Jul; 84(7):1378-82. PubMed ID: 25882963
[TBL] [Abstract][Full Text] [Related]
5. Improving the detection of small lesions using a state-of-the-art time-of-flight PET/CT system and small-voxel reconstructions.
Koopman D; van Dalen JA; Lagerweij MC; Arkies H; de Boer J; Oostdijk AH; Slump CH; Jager PL
J Nucl Med Technol; 2015 Mar; 43(1):21-7. PubMed ID: 25613334
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of sarcoidosis-lymphoma syndrome lesions: a case report on the use of two different positron emission tomography tracers.
Yudistiro R; Arisaka Y; Tokue A; Nakajima T
BMC Med Imaging; 2016 Jan; 16():1. PubMed ID: 26746426
[TBL] [Abstract][Full Text] [Related]
7. Classification of thresholded regions based on selective use of PET, CT and PET-CT image features.
Lei Bi ; Jinman Kim ; Feng DD; Fulham M
Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():1913-6. PubMed ID: 25570353
[TBL] [Abstract][Full Text] [Related]
8. Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.
Wang LJ; Wu HB; Wang M; Han YJ; Li HS; Zhou WL; Wang QS
Eur J Radiol; 2015 Nov; 84(11):2275-9. PubMed ID: 26388466
[TBL] [Abstract][Full Text] [Related]
9. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
10. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
11. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
[TBL] [Abstract][Full Text] [Related]
12. PET/MRI for the evaluation of patients with lymphoma: initial observations.
Heacock L; Weissbrot J; Raad R; Campbell N; Friedman KP; Ponzo F; Chandarana H
AJR Am J Roentgenol; 2015 Apr; 204(4):842-8. PubMed ID: 25794075
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
[TBL] [Abstract][Full Text] [Related]
14. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
15. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
16. Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study.
Besson FL; de Boysson H; Parienti JJ; Bouvard G; Bienvenu B; Agostini D
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):155-66. PubMed ID: 24008434
[TBL] [Abstract][Full Text] [Related]
17. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
18. [Importance of PET/CT in lymphoma diagnostics].
Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
[TBL] [Abstract][Full Text] [Related]
19. Effect of time-of-flight technique on the diagnostic performance of 18F-FDG PET/CT for assessment of lymph node metastases in head and neck squamous cell carcinoma.
Li CY; Klohr S; Sadick H; Weiss C; Hoermann K; Schoenberg SO; Sadick M
J Nucl Med Technol; 2014 Sep; 42(3):181-7. PubMed ID: 24970897
[TBL] [Abstract][Full Text] [Related]
20. Does enhanced CT influence the biological GTV measurement on FDG-PET images?
Vera P; Modzelewski R; Hapdey S; Gouel P; Tilly H; Jardin F; Ruan S; Gardin I
Radiother Oncol; 2013 Jul; 108(1):86-90. PubMed ID: 23618503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
